PHILADELPHIA, PA — May 23, 2002 —
Aripiprazole, a new investigational antipsychotic drug, is showing promise for the treatment of acute mania in patients with bipolar disorder, according to new research. Studies on the drug were presented here this week at the annual meeting of the American Psychiatric Association (APA).
As part of a Phase III, multicenter, double-blind, randomized, placebo-controlled trial, 262 patients diagnosed with acute mania were treated with either aripiprazole or placebo. The study’s lead author was Paul E. Keck, Jr, MD, from the department of psychiatry at the University of Cincinnati College of Medicine in Ohio, United States. On day 4, patients in the treatment group began to show more improvement than the placebo group with respect to acute manic symptoms.
These included elevated mood, irritability, thought disorder, abnormal thought content, and disruptive-aggressive behavior. A significant difference, which increased as the three-week trial progressed, was also found between the two groups with respect to mean change from baseline on the total score of the Young Mania Rating Scale (Y-MRS), with the aripiprazole group showing more improvement than the placebo group.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!